drugset / Trial / NCT04746339
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
Phase 4
Terminated
411 enrolled
Brazilian Clinical Research Institute
Beneficência Portuguesa de São Paulo · collabBrazilian Research In Intensive Care Network · collabHospital Alemão Oswaldo Cruz · collabHospital Israelita Albert Einstein · collabHospital Moinhos de Vento · collabHospital Sirio-Libanes · collabHospital do Coracao · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2022-05-13
- Completion
- 2022-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apixaban | Small molecule | 2.5 mg | Oral |